CHE · Insider Trading
Chemed Corporation
Every open-market purchase and sale reported by CHE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-22 | Kevin J McNamara | president and CEO | A | +36,693 deriv. | — |
| 2026-10-22 | Joel L Wherley | CEO - Vitas Healthcare | A | +12,686 deriv. | — |
| 2026-10-22 | Michael D Witzeman | VP & Chief Financial Officer | A | +12,686 deriv. | — |
| 2026-10-22 | Spencer S Lee | executive vice president | A | +7,125 deriv. | — |
| 2026-10-22 | Thomas C Hutton | vice president | A | +3,964 deriv. | — |
| 2026-10-22 | Brian C Judkins | VP and Chief Legal Officer | A | +9,392 deriv. | — |
| 2026-10-01 | Spencer S Lee | executive vice president | MIXED | +939 | −$291.37K |
| 2026-09-30 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$1.03M |
| 2026-09-29 | Thomas C Hutton | vice president | MIXED | +359 | −$101.87K |
| 2026-09-21 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$1.00M |
| 2026-08-24 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$1.08M |
| 2026-08-24 | Spencer S Lee | executive vice president | Sell | −1,000 | −$541.04K |
| 2026-08-10 | Brian C Judkins | VP and Chief Legal Officer | MIXED | +908 | −$204.64K |
| 2026-08-06 | Joel L Wherley | CEO - Vitas Healthcare | MIXED | +329 | −$74.28K |
| 2026-08-06 | Joel L Wherley | CEO - Vitas Healthcare | MIXED | +329 | −$74.28K |
| 2026-08-04 | Kevin J McNamara | president and CEO | MIXED | −19,801 | −$10.67M |
| 2026-08-03 | Patrick P Grace | Director | Sell | −190 | −$101.08K |
| 2026-06-10 | Andrea R Lindell | Director | Sell | −1,347 | −$602.55K |
| 2026-05-29 | George J Walsh III | Director | Sell | −500 | −$218.91K |
| 2026-05-19 | Ron DeLyons | Director | A | +386 | +$170.14K |
| 2026-05-19 | Patrick P Grace | Director | A | +386 | +$170.14K |
| 2026-05-19 | Christopher J Heaney | Director | A | +386 | +$170.14K |
| 2026-05-19 | Andrea R Lindell | Director | A | +386 | +$170.14K |
| 2026-05-19 | Eileen P McCarthy | Director | A | +386 | +$170.14K |
| 2026-05-19 | John Meredith Mount Jr. | Director | A | +386 | +$170.14K |
| 2026-05-19 | George J Walsh III | Director | A | +386 | +$170.14K |
| 2026-05-08 | Patrick P Grace | Director | Sell | −60 | −$25.55K |
| 2026-05-04 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$842.26K |
| 2026-03-30 | Kevin J McNamara | president and CEO | Sell | −1,500 | −$554.05K |
| 2026-03-13 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$806.36K |
| 2026-02-17 | Brian C Judkins | VP and Chief Legal Officer | MIXED | +249 | +$116.92K |
| 2026-02-17 | Kevin J McNamara | president and CEO | MIXED | +1,522 | +$714.67K |
| 2026-02-17 | Michael D Witzeman | VP & Chief Financial Officer | MIXED | +293 | +$137.58K |
| 2026-02-17 | Joel L Wherley | CEO - Vitas Healthcare | MIXED | +193 | +$90.63K |
| 2026-02-17 | Thomas C Hutton | vice president | MIXED | +127 | +$59.63K |
| 2026-02-17 | Spencer S Lee | executive vice president | MIXED | +345 | +$162.00K |
| 2025-12-29 | Andrea R Lindell | Director | G | −463 | — |
| 2025-11-25 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$875.10K |
| 2025-11-19 | Spencer S Lee | executive vice president | G | −60 | — |
| 2025-10-22 | Kevin J McNamara | president and CEO | A | +58,672 deriv. | — |
| 2025-10-22 | Thomas C Hutton | vice president | A | +6,338 deriv. | — |
| 2025-10-22 | Michael D Witzeman | VP & Chief Financial Officer | A | +19,486 deriv. | — |
| 2025-10-22 | Brian C Judkins | VP and Chief Legal Officer | A | +15,017 deriv. | — |
| 2025-10-22 | Spencer S Lee | executive vice president | A | +12,759 deriv. | — |
| 2025-10-22 | Joel L Wherley | CEO - Vitas Healthcare | A | +17,476 deriv. | — |
| 2025-09-29 | Kevin J McNamara | president and CEO | Sell | −3,000 | −$1.38M |
| 2025-09-10 | Patrick P Grace | Director | Sell | −150 | −$69.51K |
| 2025-08-05 | Nicholas Michael Westfall | Executive Vice President | Sell | −10,012 | −$4.22M |
| 2025-08-05 | George J Walsh III | Director | Buy | +200 | +$83.42K |
| 2025-08-05 | Kevin J McNamara | president and CEO | Sell | −2,000 | −$857.10K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kevin J McNamara | president and CEO | 66,418 | $34.07M |
| Thomas C Hutton | vice president | 43,010 | $22.06M |
| Spencer S Lee | executive vice president | 26,011 | $13.34M |
| Brian C Judkins | VP and Chief Legal Officer | 9,222 | $4.73M |
| Michael D Witzeman | VP & Chief Financial Officer | 6,073 | $3.11M |
| Andrea R Lindell | Director | 4,578 | $2.35M |
| George J Walsh III | Director | 3,643 | $1.87M |
| Patrick P Grace | Director | 3,533 | $1.81M |
| Christopher J Heaney | Director | 2,775 | $1.42M |
| Ron DeLyons | Director | 2,052 | $1.05M |
| John Meredith Mount Jr. | Director | 1,316 | $674.98K |
| Eileen P McCarthy | Director | 1,241 | $636.51K |
| Joel L Wherley | CEO - Vitas Healthcare | 1,181 | $605.73K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CHE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.